Dermatomyositis as an Expression of Paraneoplastic Syndrome
Published
May 15, 2014
Almetrics
Dimensions
Google Scholar
##plugins.themes.bootstrap3.article.details##
Abstract
Dermatomyositis is an inflammatory myopathy with cutaneous compromise that has been linked to neoplastia. We introduce a 74 year old patient diagnosed with dermatomyositis who presented with dysphagia and significant weight loss, which lead to the search of a malignant association, with presence of an advanced neoplasic process requiring palliative management with no primary etiology. Due to the increased incidence of
dermatomyositis in cancer patients compared to the general population, it is of vital importance to respond to the clinical signs described as predictors of the association between cancer and DM and not think of it as a primary pathology.
Keywords
dermatomiostis, cáncer, miopatía, Dermatomyositis, cancer, myopathy,
References
1. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002; 28: 723-41.
2. Dankó K, Ponyi A, Molnar A, András C, Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol. 2009;21:594-8.
3. Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: Autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol. 2008;4:201-9.
4. Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001; 357:96-100.
5. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971.
6. Sigurgeirsson B, Lindelôf B, Edhag O et al. Risk of cancer in patients with dermatomyositis o polymyositis. N Engl J Med. 1992;326:363-7.
7. Baer A. Paraneoplastic muscle disease. Rheum Dis Clin N Am. 2011;37:185-200.
8. Zampieri S, Valente M, Adami N et al. Polymyositis, dermatomyositis and malignancy: A further intriguing link. Autoimmunity Reviews. 2010;9:449-53.
9. Levin S. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol. 2006;18:620-4.
10. Dalakas M. The molecular and celular pathology of inflammatory muscle diseases. Curr Opin Pharmacol. 2001;1: 300-6.
11. Kohei A, Hidehiro Y, Michiko O et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathicdermatomyositis. Mod Rheumatol. 2011;21:178-83.
12. Chen Y, Wu C-Y, Shen L. Predicting factors of malignancy in dermatomyositis and polymyositis: a case - control study. Br J Dermatol. 2001;144: 825-31. 13. Sparsa A, Liozon E, Herrmann F et al.
Routine vs extensive malignancy ser for adult dermatomyositis and polymyositis. Arch Dermatol. 2002;138:885-90.
14. Drake L, Dinehart S, Farmer E et al. Guidelines of care for dermatomyositis. J Am Acad Dermatol. 1996;34(5 Pt 1):824.
15. Callen JP, Hyla JF, Bole GG Jr, Key DR. The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol. 1980;116:295-8.
2. Dankó K, Ponyi A, Molnar A, András C, Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol. 2009;21:594-8.
3. Suber TL, Casciola-Rosen L, Rosen A. Mechanisms of disease: Autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol. 2008;4:201-9.
4. Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001; 357:96-100.
5. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971.
6. Sigurgeirsson B, Lindelôf B, Edhag O et al. Risk of cancer in patients with dermatomyositis o polymyositis. N Engl J Med. 1992;326:363-7.
7. Baer A. Paraneoplastic muscle disease. Rheum Dis Clin N Am. 2011;37:185-200.
8. Zampieri S, Valente M, Adami N et al. Polymyositis, dermatomyositis and malignancy: A further intriguing link. Autoimmunity Reviews. 2010;9:449-53.
9. Levin S. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol. 2006;18:620-4.
10. Dalakas M. The molecular and celular pathology of inflammatory muscle diseases. Curr Opin Pharmacol. 2001;1: 300-6.
11. Kohei A, Hidehiro Y, Michiko O et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathicdermatomyositis. Mod Rheumatol. 2011;21:178-83.
12. Chen Y, Wu C-Y, Shen L. Predicting factors of malignancy in dermatomyositis and polymyositis: a case - control study. Br J Dermatol. 2001;144: 825-31. 13. Sparsa A, Liozon E, Herrmann F et al.
Routine vs extensive malignancy ser for adult dermatomyositis and polymyositis. Arch Dermatol. 2002;138:885-90.
14. Drake L, Dinehart S, Farmer E et al. Guidelines of care for dermatomyositis. J Am Acad Dermatol. 1996;34(5 Pt 1):824.
15. Callen JP, Hyla JF, Bole GG Jr, Key DR. The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol. 1980;116:295-8.
How to Cite
Mejía-López, M. G., Alvarado-Ospina, Y. A., Gutiérrez, J. M., Fernández-Ávila, D. G., & Díaz, M. C. (2014). Dermatomyositis as an Expression of Paraneoplastic Syndrome. Universitas Medica, 55(3), 334–339. https://doi.org/10.11144/Javeriana.umed55-3.dces
Issue
Section
Case Reports